Regulatory GSK eyes October FDA verdict on chronic hep B drug PharmaphorumGSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.Infectious DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. Infectious Disease Read full story Post navigation Previous: Merck KGaA and Remepy join forces to develop combo drug-digital therapiesNext: Coultreon banks $125M to support testing of former Galapagos immune drug Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
